CARSGEN-B Shares Surge Over 7% in Session as CT041 Passes Initial Review for 2026 Commercial Health Insurance Innovation Drug Catalog

Deep News07-16 11:50

Shares of CARSGEN-B (HKEX: 02171) rose more than 7% during the trading session. At the time of writing, the stock is up 5.32% to HK$16.83, with a trading turnover of HK$52.48 million.

On July 16th, CARSGEN announced that, according to a notice from the National Healthcare Security Administration, its product Kailimei® (SuRuiji Orelencel Injection, product code: CT041, a Claudin18.2-targeted autologous CAR-T cell therapy candidate) has successfully passed the preliminary formal review for the 2026 National Commercial Health Insurance Innovation Drug Catalog adjustment. As the world's first approved CAR-T therapy for solid tumors, this product marks a historic leap in cellular immunotherapy from hematological malignancies to solid tumors, precisely addressing a critical clinical gap in the treatment of advanced gastric cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189418681?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189418681","market":"sg","top_or_hot":-1,"title":"CARSGEN-B Shares Surge Over 7% in Session as CT041 Passes Initial Review for 2026 Commercial Health Insurance Innovation Drug Catalog","media":"Deep News","content":"<p>Shares of <b>CARSGEN-B</b> (<b>HKEX: 02171</b>) rose more than 7% during the trading session. At the time of writing, the stock is up 5.32% to HK$16.83, with a trading turnover of HK$52.48 million.<br><br>\nOn July 16th, CARSGEN announced that, according to a notice from the National Healthcare Security Administration, its product Kailimei® (SuRuiji Orelencel Injection, product code: CT041, a Claudin18.2-targeted autologous CAR-T cell therapy candidate) has successfully passed the preliminary formal review for the 2026 National Commercial Health Insurance Innovation Drug Catalog adjustment. As the world's first approved CAR-T therapy for solid tumors, this product marks a historic leap in cellular immunotherapy from hematological malignancies to solid tumors, precisely addressing a critical clinical gap in the treatment of advanced gastric cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARSGEN-B Shares Surge Over 7% in Session as CT041 Passes Initial Review for 2026 Commercial Health Insurance Innovation Drug Catalog</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARSGEN-B Shares Surge Over 7% in Session as CT041 Passes Initial Review for 2026 Commercial Health Insurance Innovation Drug Catalog\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-07-16 11:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>CARSGEN-B</b> (<b>HKEX: 02171</b>) rose more than 7% during the trading session. At the time of writing, the stock is up 5.32% to HK$16.83, with a trading turnover of HK$52.48 million.<br><br>\nOn July 16th, CARSGEN announced that, according to a notice from the National Healthcare Security Administration, its product Kailimei® (SuRuiji Orelencel Injection, product code: CT041, a Claudin18.2-targeted autologous CAR-T cell therapy candidate) has successfully passed the preliminary formal review for the 2026 National Commercial Health Insurance Innovation Drug Catalog adjustment. As the world's first approved CAR-T therapy for solid tumors, this product marks a historic leap in cellular immunotherapy from hematological malignancies to solid tumors, precisely addressing a critical clinical gap in the treatment of advanced gastric cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1585","symbol_name":"昨日强势股","start_time":0,"source_url":"","article_id":"1189418681","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189418681","pubTimestamp":1784173827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shares of CARSGEN-B (HKEX: 02171) rose more than 7% during the trading session. At the time of writing, the stock is up 5.32% to HK$16.83, with a trading turnover of HK$52.48 million. On July 16th,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BK1585":"昨日强势股","06978":"永泰生物-B","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK1161":"生物科技","02171":"科济药业-B","MEDX":"HORIZON KINETICS MEDICAL ETF","BK1587":"次新股","BK1574":"生物医药B类股"},"translate_title":"CT041通过2026年商业健康险创新药品目录初审，CARSGEN-B股价盘中飙升逾7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"IBBQ":1,"02171":1,"06978":1,"MEDX":1},"content_text":"Shares of CARSGEN-B (HKEX: 02171) rose more than 7% during the trading session. At the time of writing, the stock is up 5.32% to HK$16.83, with a trading turnover of HK$52.48 million.\nOn July 16th, CARSGEN announced that, according to a notice from the National Healthcare Security Administration, its product Kailimei® (SuRuiji Orelencel Injection, product code: CT041, a Claudin18.2-targeted autologous CAR-T cell therapy candidate) has successfully passed the preliminary formal review for the 2026 National Commercial Health Insurance Innovation Drug Catalog adjustment. As the world's first approved CAR-T therapy for solid tumors, this product marks a historic leap in cellular immunotherapy from hematological malignancies to solid tumors, precisely addressing a critical clinical gap in the treatment of advanced gastric cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189418681","isCrawlerRequest":true}